Nasdaq

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...
Nasdaq

Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome

Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...

MapLight Therapeutics, Inc.: MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

MapLight Therapeutics, Inc. ("MapLight") (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Seeking Alpha

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies ...
The National Law Review

Cellphire Therapeutics CLPH-511 Fast Track Designation Granted

FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply ROCKVILLE, Md., March 17, 2025 ...
Seeking Alpha

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, ...